Dame Sarah Catherine Gilbert is a distinguished English vaccinologist and Professor of Vaccinology at the University of Oxford. She co-founded Vaccitech and has dedicated her career to the development of vaccines against influenza and emerging viral pathogens. Gilbert’s groundbreaking work led to the creation of a universal flu vaccine, which underwent clinical trials in 2011, showcasing her commitment to advancing public health through innovative research.

In January 2020, Gilbert’s swift response to a report on a novel pneumonia outbreak in Wuhan resulted in the rapid design of a vaccine against COVID-19. By December 30, 2020, the Oxford–AstraZeneca COVID-19 vaccine, co-developed with the Oxford Vaccine Group, received approval for use in the UK. This vaccine has since been distributed globally, with over 3 billion doses supplied, significantly contributing to the fight against the pandemic.

Gilbert’s academic journey began with a Bachelor of Science degree in biological sciences from the University of East Anglia, followed by a PhD from the University of Hull. She has held various prestigious positions, including University lecturer and Reader in Vaccinology at Oxford, and became a Professor at the Jenner Institute in 2010. Her research focuses on viral vectored vaccines, which induce strong immune responses, and she has been instrumental in developing vaccines for diseases such as MERS and Nipah virus.

In recognition of her contributions to science and public health, Gilbert has received numerous accolades, including the Rosalind Franklin medal and the Freedom of the City of London. She co-authored the bestselling book “Vaxxers,” detailing the development of the Oxford–AstraZeneca vaccine. Gilbert continues to inspire future generations of scientists and remains a pivotal figure in the field of vaccinology.